Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8790105 | 0.92 | ABCG2 (0.61) | ABCG2ABCB1MAPTTP53MEN1 | |
| SCHEMBL8789166 | 0.90 | ABCG2 (0.65) | ABCG2ABCB1MAPTTP53MEN1 | |
| SCHEMBL8789662 | 0.88 | ABCG2 (0.64) | ABCG2ABCB1MAPTTP53MEN1 | |
| SCHEMBL8789486 | 0.87 | ABCG2 (0.61) | ABCG2ABCB1MAPTTP53KLKB1 | |
| SCHEMBL8788906 | 0.86 | ABCG2 (0.69) | ABCG2ABCB1MAPTTP53MEN1 | |
| SCHEMBL8790755 | 0.86 | ABCG2 (0.58) | ABCG2ABCB1MAPTTP53MEN1 | |
| SCHEMBL8789648 | 0.85 | ABCG2 (0.63) | ABCG2ABCB1MAPTTP53MEN1 | |
| SCHEMBL8789872 | 0.85 | ABCG2 (0.57) | ABCG2ABCB1MAPTTP53MEN1 | |
| SCHEMBL8790168 | 0.84 | ABCG2 (0.62) | ABCG2ABCB1MAPTTP53KLKB1 | |
| SCHEMBL8789962 | 0.84 | ABCG2 (0.65) | ABCG2ABCB1MAPTTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |